Instil Bio, Inc.

Instil Bio, Inc. (TIL) priced its initial public offering on Mar 22, 2021 at $20.00 per share, within its $19.00–$20.00 range, raising $320M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.52B. Cooley advised the company and Latham & Watkins advised the underwriters.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company developing autologous tumor infiltrating lymphocyte (TIL) cell therapies for cancer. Its lead candidate, ITIL-168, targets advanced melanoma, with an IND submission and a Phase 2 trial planned for the second half of 2021.

Status

IPO

Ticker

TIL

Exchange

Nasdaq Global Select

Priced

Mar 22, 2021

IPO price

$20.00

Price range

$19.00–$20.00

Raised

$320M

Market cap at IPO price

$2.52B

First filed

Feb 26, 2021

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.